---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-112184"
form_type: "8-K"
ticker: "APUS"
cik: "0001894525"
company_name: "Apimeds Pharmaceuticals US, Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:52:57.022763+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Apimeds boosts CEO salary to $500K and adds 24-month severance with equity vesting

## Summary
- CEO Erik Emerson's annual base salary increased to $500,000, effective Nov 13, 2025.
- If terminated without cause, Emerson gets 24 months salary/benefits plus immediate vesting of all unvested equity.
- On termination for cause or voluntary quit without good reason, unvested equity forfeited automatically.
- Amendment modifies the original Sept 21, 2023 employment agreement.

## SEC filing metadata
- accession: 0001213900-25-112184
- form_type: 8-K
- ticker: APUS
- cik: 0001894525
- company_name: Apimeds Pharmaceuticals US, Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894525/000121390025112184/0001213900-25-112184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894525/000121390025112184/ea0266166-8k_apimeds.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-112184
- JSON: https://secwatch.observer/filing/0001213900-25-112184.json
- Plain text: https://secwatch.observer/filing/0001213900-25-112184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.